<DOC>
	<DOCNO>NCT02031055</DOCNO>
	<brief_summary>The purpose study evaluate , patient advance solid tumor , mass balance FTD TPI single dose TAS-102 light tracer dose [ 14C ] FTD [ 14C ] TPI .</brief_summary>
	<brief_title>Study Mass Balance Oral FTD TPI Components TAS-102 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase 1 , open-label study evaluate mass balance FTD TPI single dose TAS-102 light tracer dose [ 14C ] FTD [ 14C ] TPI . The study conduct 2 part : mass balance part TAS-102 extension part . After completion mass balance part , patient receive continued treatment TAS-102 study extension part .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>1 . Has advance solid tumor ( exclude previously treat breast cancer ) standard therapy exist 2 . ECOG performance status 0 1 3 . Is able take medication orally 4 . Has adequate organ function ( bone marrow , kidney liver ) 5 . Women childbearing potential must negative pregnancy test must agree adequate birth control conception possible . Males must agree adequate birth control . 1 . Has certain recent treatment e.g . anticancer therapy , receive investigational agent , within specified time frame prior study drug administration 2 . Certain serious illness medical condition ( ) 3 . Has either partial total gastrectomy 4 . Has medical condition jeopardizes impair ability collect representative excreta 5 . Has unresolved toxicity great equal CTCAE Grade 2 attribute prior therapy 6 . Known sensitivity TAS102 components 7 . Is pregnant lactate female 8 . Refuses use adequate mean contraception ( include male patient ) 9 . Is occupationally expose worker define relevant ionizing radiation regulation 10 . Has expose 14C last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Advanced solid tumor</keyword>
</DOC>